Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma

Table 6

Univariate and multivariate analysis results of disease-free and overall survival in patients with T1 lung adenocarcinoma, excluding those at stage 0.

Factor	Univariate analysis			Multivariate analysis
	HR	95% CI		HR	95% CI
Disease-free survival
Sex (female versus male)	2.320	1.072–5.023	0.033	1.377	0.601–3.157	0.450
CEA (<2.12 versus ≥2.12)	5.203	2.086–12.977	<0.001	3.016	1.104–8.241	0.031
Tumour size (pT1a versus pT1b versus pT1c)	2.235	1.464–3.412	<0.001	1.580	0.800–3.119	0.188
Histology (MIA versus IAC)	7.971	1.881–33.772	0.005	1.913	0.224–16.317	0.553
Lymphatic metastasis (absent versus present)	7.183	3.117–16.553	<0.001	19.612	3.888–98.923	<0.001
Pathological stage (stage I versus II, and IIIA)	2.054	1.263–3.340	0.004	0.342	0.147–0.793	0.012
Overall survival
Sex (female versus male)	3.332	1.208–9.188	0.020	2.090	0.312–14.004	0.447
Smoking (non versus current/former)	2.817	1.047–7.578	0.040	1.263	0.127–12.561	0.842
CEA (<2.12 versus ≥2.12)	11.244	2.552–49.537	0.001	2.643	0.352–19.842	0.345
EGFR mutation (exon 21 versus exon 19)	5.974	1.124–31.746	0.036	7.221	1.133–46.003	0.036
Tumour size (pT1a versus pT1b versus pT1c)	3.351	1.698–6.613	<0.001	6.019	1.036–34.958	0.046
Lymphatic metastasis (absent versus present)	7.147	2.479–20.606	<0.001	14.645	0.170–1258.671	0.238
Pathological stage (stage I versus II, and IIIA)	1.898	1.011–3.564	0.046	0.449	0.045–4.503	0.496

HR: hazard ratio; CI: confidence interval; CEA: carcinoembryonic antigen; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IAC: invasive adenocarcinoma. .